Article

Early T Cell and Binding Antibody Responses are Associated with COVID-19 RNA Vaccine Efficacy Onset

2021-03-02

Abstract excerpt

RNA vaccines against Covid-19 have demonstrated ~95% efficacy in Phase III clinical trials. Although complete vaccination consisted of two-doses, the onset of protection for both licensed RNA vaccines was observed as early as 12 days after a single dose. The adaptive immune response that coincides with this onset of protection could represent the necessary elements of immunity against Covid-19. Herein, we tracked...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fbb7a4c1-f5c3-509c-b472-c46975036b63
DOI: 10.2139/ssrn.3796533

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early T Cell and Binding Antibody Responses are Associated with COVID-19 RNA Vaccine Efficacy OnsetDOI 10.2139/ssrn.3796533Read

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onsetSemantic proximity Read

Determinants of early antibody responses to COVID-19 mRNA vaccines in exposed and naive healthcare workersSemantic proximity Read

Active immunization by COVID-19 mRNA vaccine results in rapid antibody response and virus reduction in breakthrough infection by Delta (B.1.617.2)Semantic proximity Read

Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort studySemantic proximity Read

Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort StudySemantic proximity Read

Early Mucosal Type II Interferon Limits SARS-CoV-2 Replication in HumansSemantic proximity Read

Longitudinal analyses after COVID-19 recovery or prolonged infection reveal unique immunological signatures after repeated vaccinationsSemantic proximity Read

Real-world monitoring of BNT162b2 vaccine-induced SARS-CoV-2 B and T cell immunity in naive healthcare workers: a prospective single center studySemantic proximity Read

Mucosal Immune Response in BNT162b2 COVID-19 Vaccine RecipientsSemantic proximity Read

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workersSemantic proximity Read

More rapid, robust and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individualsSemantic proximity Read

Influence of past infection with SARS-CoV-2 on the response to the BioTech/Pfizer BNT162b2 mRNA vaccine in health care workers: kinetics and durability of the humoral responseSemantic proximity Read